Charles A. Deignan

Equibles does not estimate personal net worth.

About Charles A. Deignan

Earlier roles on record: CFO at Clearside Biomedical, Inc. (CLSDQ) until July 18, 2025. The proxy statement of Clearside Biomedical, Inc. reports total compensation of $854,406 for Charles A. Deignan in fiscal 2023, including a base salary of $409,000. Disclosed compensation is on record for 6 fiscal years.

Affiliation history

Clearside Biomedical, Inc. (CLSDQ)
CFO

Proxy statement

Start not stated–2025-07-18

Company network

Clearside Biomedical, Inc.

CLSDQ

Biotechnology · Healthcare

CFO

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2023	Clearside Biomedical, Inc. (CLSDQ)	Chief Financial Officer	$409,000	—	—	$285,730	$148,876	$10,800	$854,406
2022	Clearside Biomedical, Inc. (CLSDQ)	Chief Financial Officer	$388,650	—	$101,288	$237,791	$138,250	$10,050	$876,029
2021	Clearside Biomedical, Inc. (CLSDQ)	Chief Financial Officer	$353,163	$14,000	$386,404	$647,601	$134,048	$9,600	$1,544,816
2020	Clearside Biomedical, Inc. (CLSDQ)	Chief Financial Officer	$342,876	—	$59,250	$152,010	$78,004	$9,450	$641,590
2019	Clearside Biomedical, Inc. (CLSDQ)	Chief Financial Officer	$332,890	—	$105,264	$107,753	$106,000	$9,300	$661,207
2018	Clearside Biomedical, Inc. (CLSDQ)	Chief Financial Officer	$330,065	$7,500	—	—	$88,096	$8,700	$434,361

Recent activity

No call appearances or filed executive changes recorded yet.